[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100361717":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":27,"locations":34,"responsibleParty":67,"collaborators":18,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":18,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":18,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":18,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Aga Khan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vitamin D supplement","EXPERIMENTAL","The intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician whereas",[13],"Drug: Vitamin D",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","control group will receive Metformin treatment during the study period.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Vitamin D","Vitamin D supplementation",[9],[26],"Metformin",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Rehana K Rehman, PhD","CONTACT","00922134864460","4460","drrehana7@gmail.com",[35,59],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Dr Rehana Rehman","RECRUITING","Karachi","Sindh","74800","Pakistan","PK",{"type":44,"coordinates":45},"Point",[46,47],67.0104,24.8608,{"lat":47,"lon":46},[50,54],{"name":51,"role":30,"phone":52,"phoneExt":18,"email":53},"Rehana Rehman","03072227775","rehana.rehman@aku.edu",{"name":55,"role":30,"phone":56,"phoneExt":57,"email":58},"Arfa Azhar","00922134864473","4473","arfa.azhar@aku.edu",{"facility":36,"status":37,"city":38,"state":39,"zip":60,"country":41,"countryCode":42,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},"75500",{"type":44,"coordinates":62},[46,47],{"lat":47,"lon":46},[65,66],{"name":51,"role":30,"phone":52,"phoneExt":18,"email":53},{"name":55,"role":30,"phone":56,"phoneExt":57,"email":58},{"type":68,"investigatorFullName":51,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Associate Professor","100361717","phase-2-vitamin-d-and-polycystic-ovarian-syndrome-pcos-100361717",false,"NCT03989778","Vitamin D and Polycystic Ovarian Syndrome (PCOS)","Efficacy of Vitamin D Supplementation and Metformin Compared to Metformin Alone for Improvement in Follicle Size of Infertile Females With Polycystic Ovary Syndrome: a Randomized Open Label Trial","Inclusion Criteria:\n\n* Females with age range 18- 36 years, from all ethnic background having primary infertility with diagnosis of PCOS when at least 2 of these 3 elements are present: hyperandrogenism, chronic anovulation and polycystic ovaries and Vitamin D deficiency serum levels \\\u003C 25 nmol\u002FL\n\nExclusion Criteria:\n\nexclusion criteria at baseline will be excluded from the study\n\n* Females with secondary Infertility\n* Hypercalcemia (plasma calcium concentrations\\> 2.65 mmol\u002FL)\n* Exclude women with Tuberculosis or other granulomatous disorders.\n* Women receiving vitamin D replacement, oral contraceptives, hormonal replacement therapy, glucocorticoids, calcium supplementation, insulin-sensitizing drugs(incretin mimetic drugs, thiazolidinedione, sulfonylurea), lipid-lowering drugs or other drugs affecting insulin sensitivity or serum androgens (e.g., niacin, corticosteroids, beta-blockers, calcium channel blockers, thiazide diuretics), anti-epileptics, anti-retroviral, cholestyramine, anti-fungal, statins, H2 blockers, immunosuppressants, chemotherapeutic agents, antimicrobials (Rifampicin, isoniazid, hydroqychloroquin) or any other drug modifying lipid metabolism in the previous 3 months prior to study\n* Women with congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors, type 2 diabetes mellitus, renal, hepatic or thyroid disorders, hyperparathyroidism, malabsorption syndromes, Chronic Kidney Disease Hepatic failure, cystic fibrosis, vaginal bleeding of unknown etiology Women Those who had Bariatric surgery will also be excluded.",true,"ALL","18 Years","36 Years",{"count":82,"type":83},300,"ESTIMATED","INTERVENTIONAL",[86],"PHASE2","Primary Objectives:\n\nTo evaluate the efficacy of metformin and Vitamin D supplementation on serum insulin and serum androgen levels (Total testosterone, Steroid Hormone Binding Globulin, Free Androgen Index) levels compared metformin alone in infertile Poly cystic ovarian females of reproductive age group.\n\nSecondary Objectives:\n\nTo measure change in endometrial thickness\u002Fnumber of follicles and follicular size by day 12 trans-vaginal ultrasound in the intervention group i.e. combination of metformin and vitamin D supplementation",[89,90,91],"Infertility, Female","Infertility","Vitamin D Deficiency","2025-02-17",{"date":94,"type":95},"2025-02-19","ACTUAL",{"date":97,"type":95},"2023-02-01",{"date":99,"type":83},"2025-07-13",{"name":5,"class":6},2]